Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects lirilumab and azacitidine and to see how well
they work in treating patients with acute myeloid leukemia that has not responded to
treatment or has returned after a period of improvement. Monoclonal antibodies, such as
lirilumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving lirilumab with azacitidine may be an effective treatment for relapsed or
refractory acute myeloid leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)